Due to the growing incidence of low drug solubility in the pharmaceutical discovery and development pipeline the number of enabling technologies that are employed to improve oral drug absorption and bioavailability (BA) are also growing. Most commonly utilized are particle size reduction, amorphous solid dispersions and lipid-based technologies. Facilitated by advances in predictive methodologies, amorphous solid dispersions have become the most prevalent commercially deployed BA technology. To learn more, please download our whitepaper.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center